ClinicalTrials.gg
CompletedNCT03738150SPECTRAUpdated Aug 27, 2024Results posted

A Study of Sotatercept for the Treatment of Pulmonary Arterial Hypertension

A Phase 2 interventional study of Sotatercept and SOC in Pulmonary Arterial Hypertension, sponsored by Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA. Completed at 4 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-08-27.

Sponsored by Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA (part of Merck & Co., Inc) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
21
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 18 studies testing sotatercept in Pulmonary Arterial Hypertension — 7 open to participants now, 10 under way, 1 of them phase 3. sotatercept · Pulmonary Arterial Hypertension.

Enrollment
15th of 18
21 · median 44
Started
2019
the only one that year
Phase 2
7 of 18
3 open now
Registered
2nd of 18
by date
Lead sponsor
5 of 18
Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA

Among the 18 studies testing sotatercept in Pulmonary Arterial Hypertension, this one is the 15th largest by enrollment, is the only one that started in 2019, is one of 7 in phase 2, and was the 2nd registered.

Pulmonary Arterial Hypertension

700 studies on the registry are indexed under Pulmonary Arterial Hypertension; 141 are open to participants now.

Browse Pulmonary Arterial Hypertension studies →

Open to participants now

7 of the 18 studies testing sotatercept in Pulmonary Arterial Hypertension are open now, in 12 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About sotatercept

sotatercept: first FDA approval 2024 (WINREVAIR), first EMA approval 2024. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 90 Pulmonary Arterial Hypertension studies recruiting now, 51 (57%) set no upper age limit and 24 (27%) stop at 75 or younger; 18 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies testing sotatercept in Pulmonary Arterial Hypertension, or all of them as a file.
02

Study summary

This study evaluates the effect of sotatercept (ACE-011) in adults with pulmonary arterial hypertension (PAH). Each eligible participant will receive standard of care (SOC) plus sotatercept (ACE-011) for a 24-week treatment period, followed by an 18-month extension period, and an 8-week follow-up period.

Read the detailed description

This is a Phase 2a, single-arm, open-label, multicenter exploratory study to determine the effects of sotatercept plus SOC in adults with WHO functional class III PAH.

All eligible participants will receive SOC plus sotatercept at a starting dose level of 0.3 mg/kg by subcutaneous (SC) injection for Cycle 1 and escalating to 0.7 mg/kg at Cycle 2 for the remainder of the treatment period. Participants will be required to attend clinic visits once every three weeks for the 24-week treatment period and once every three weeks for the 18-month extension period to perform one or more protocol specified evaluations. Evaluations include hemodynamic measures collected during right heart catheterization (RHC) with invasive cardiopulmonary exercise test (iCPET), and cardiac magnetic resonance imaging (MR), 6-minute walk distance (6MWD), pharmacokinetic parameters, pharmacodynamic parameters, anti-drug antibody testing, and adverse events.

03

Conditions studied

  • Pulmonary Arterial Hypertension

Keywords

  • PAH
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥ 18 years
  2. Documented findings on RHC at any time prior to Screening consistent with a diagnosis of World Health Organization (WHO) pulmonary hypertension Group 1: PAH of any of the following subtypes:

    • Idiopathic PAH
    • Heritable PAH
    • Drug- or toxin-induced PAH
    • PAH associated with connective tissue disease
    • PAH associated with simple, congenital systemic-to-pulmonary shunts at least 1 year following shunt repair
  3. Symptomatic pulmonary hypertension classified as WHO functional class III
  4. Screening RHC documenting a minimum PVR of ≥ 4 Wood units
  5. Pulmonary function tests within 6 months prior to Screening as follows:

    1. Total lung capacity > 70% predicted; or if between 60% to 70% predicted, or not possible to be determined, confirmatory high-resolution computed tomography (CT) indicating no more than mild interstitial lung disease per investigator interpretation or
    2. Forced expiratory volume (first second) ()/forced vital capacity (FVC) > 70% predicted
    3. For subjects with a history of lobectomy or pneumonectomy, and for whom there are no population-based normalization methods, assessment based on residual lung volume will be permitted to assess eligibility.
  6. Ventilation-perfusion (VQ) scan (or, if unavailable, a negative CT pulmonary angiogram [CTPA] or pulmonary angiography result), any time prior to Screening or conducted during Screening Period with normal or low probability result
  7. 6MWD ≥ 100 and ≤ 550 meters repeated twice during Screening Period and both values within 15% of each other, calculated from the highest value
  8. Combination PAH therapy at stable (per investigator) dose levels for at least 90 days prior to Cycle 1 Day 1 (C1D1)

Exclusion criteria

Exclusion Criteria:

Participants will be excluded from the study if they meet any of the following criteria:

  1. Started or stopped receiving any general supportive therapy for pulmonary hypertension (e.g., diuretics, oxygen, anticoagulants, digoxin) within 60 days prior to C1D1 (Cycle 1 Day 1)
  2. Received intravenous inotropes (e.g., dobutamine, dopamine, norepinephrine, vasopressin) within 30 days prior to C1D1
  3. History of atrial septostomy within 180 days prior to Screening
  4. History of more than mild obstructive sleep apnea that is untreated
  5. History of portal hypertension or chronic liver disease, defined as mild to severe hepatic impairment ( Classes A to C)
  6. History of infection-associated PAH
  7. Prior exposure to sotatercept (ACE-011) or luspatercept (ACE-536)
  8. Uncontrolled systemic hypertension as evidenced by sitting systolic BP > 160 mm Hg or sitting diastolic BP > 100 mm Hg during Screening after a period of rest
  9. Systolic BP \< 90 mm Hg during Screening or at baseline
  10. History of known pericardial constriction
  11. (ECG) with > 480 msec during Screening or C1D1
  12. History of personal or family history of long QTc syndrome or sudden cardiac death
  13. History of restrictive or constrictive cardiomyopathy
  14. \< 45% on echocardiogram performed within 6 months of Screening OR pulmonary capillary wedge pressure (PCWP) > 15 mm Hg on RHC during baseline evaluation
  15. Any current symptomatic coronary disease (myocardial infarction, percutaneous coronary intervention, coronary artery bypass graft surgery, or cardiac anginal chest pain in the past 6 months prior to Screening)
  16. Acutely decompensated heart failure within 30 days prior to C1D1, as per investigator assessment
  17. Significant (≥ 2+ regurgitation) mitral regurgitation or aortic regurgitation valvular disease
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
21 participants (actual)

Study arms

  • Experimental
    Sotatercept

    Each participant will receive SOC plus sotatercept at a dose of 0.3 mg/kg SC for Cycle 1. (Each cycle will be 21 days.) From Cycle 2 through Cycle 9, the dose will be escalated to 0.7 mg/kg SC. Dosing will be every three weeks during the 24-week treatment period and 18-month extension period.

    Biological: Sotatercept · Other: SOC

Interventions

  • BiologicalSotatercept

    Sotatercept injection

    Also known as: ACE-011

  • OtherSOC

    SOC therapy refers to combination therapy consisting of drugs from two or more of the following drug classes: an endothelin-receptor antagonist (ERA), a phosphodiesterase 5 (PDE5) inhibitor, a soluble guanylate cyclase stimulator, and/or a prostacyclin analogue or receptor agonist.

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Peak Oxygen Uptake (VO2 Max) at 24 Weeks

    Each participant's VO2 max was measured by an invasive cardiopulmonary exercise test (iCPET) at baseline and at 24 weeks.

    Time frame: Baseline and 24 weeks

Secondary outcomes

  1. Change From Baseline in Right Ventricular Stroke Volume (RV SV) at 24 Weeks

    Each participant's RV SV was measured by cardiac MRI at baseline and at 24 weeks.

    Time frame: Baseline and 24 weeks

  2. Change From Baseline in Right Ventricular End-Systolic Volume (RV ESV) at 24 Weeks

    Each participant's RV ESV was measured by cardiac MR imaging at baseline and at 24 weeks.

    Time frame: Baseline and 24 weeks

  3. Change From Baseline in Right Ventricular End-Diastolic Volume (RV EDV) at 24 Weeks

    Each participant's RV EDV was measured by cardiac MR imaging at baseline and at 24 weeks.

    Time frame: Baseline and 24 weeks

  4. Percent Change From Baseline in Right Ventricular Ejection Fraction (RV EF) at 24 Weeks

    Each participant's RV EF was measured by cardiac MR imaging at baseline and at 24 weeks.

    Time frame: Baseline and 24 Weeks

  5. Change From Baseline in Right Ventricular Stroke Volume Index (RV SVI) at 24 Weeks

    Each participant's RV SVI was measured by cardiac MR imaging at baseline and at 24 weeks.

    Time frame: Baseline and 24 weeks

  6. Change From Baseline in Right Ventricular (RV) Mass at 24 Weeks

    Each participant's RV mass was measured by cardiac MR imaging at baseline and at 24 weeks.

    Time frame: Baseline and 24 weeks

  7. Change From Baseline in Ventilatory Efficiency (VE/VCO2 Slope) at 24 Weeks

    VE/VCO2 slope refers to the slope of the regression line of Minute Ventilation (VE) in liters/minute in the Y-axis and corresponding carbon dioxide production per minute (VCO2) in liters/minute in the X-axis plotted with multiple measurements taken during exercise. Each participant's VE/VCO2 slope at peak exercise was measured by an iCPET at baseline and at 24 weeks.

    Time frame: Baseline and 24 weeks

  8. Change From Baseline in Cardiac Index at 24 Weeks

    Each participant's cardiac index at peak exercise was measured by iCPET at baseline and at 24 weeks.

    Time frame: Baseline and 24 weeks

  9. Change From Baseline in Mean Pulmonary Arterial Pressure at 24 Weeks

    Each participant's pulmonary arterial pressure at peak exercise was measured by iCPET at baseline and at 24 weeks.

    Time frame: Baseline and 24 weeks

  10. Change From Baseline in Arteriovenous O2 Content Difference (Ca-vO2) at 24 Weeks

    Each participant's Ca-vO2 at peak exercise was measured by iCPET at baseline and at 24 weeks.

    Time frame: Baseline and 24 weeks

  11. Change From Baseline in Pulmonary Vascular Resistance (PVR) at 24 Weeks

    Each participant's PVR, at resting supine, was measured by right heart catheterization (RHC) at baseline and at 24 weeks.

    Time frame: Baseline and 24 weeks

  12. Change From Baseline in 6-Minute Walk Distance (6MWD) at 24 Weeks

    6MWD is measured by an exercise test known as 6MWT that assesses aerobic capacity and endurance. It measures the distance covered over a time of 6 minutes and is used as an outcome measure by which to compare changes in performance capacity. Each participant's 6MWD was measured at baseline and at 24 weeks. An increase in the distance walked during the 6MWT indicates improvement in basic mobility.

    Time frame: Baseline and 24 weeks

  13. Change From Baseline in Concentration of Amino-Terminal Brain Natriuretic Propeptide (NT-proBNP) at 24 Weeks

    Each participant's laboratory biomarkers N-terminal prohormone brain-type natriuretic peptide (NT-proBNP) or brain-type natriuretic peptide (BNP) were measured at baseline and at 24 weeks.

    Time frame: Baseline and 24 Weeks

  14. Change From Baseline in WHO (World Health Organization) Functional Class at 24 Weeks

    The World Health Organization (WHO) functional class describes how severe a person's pulmonary hypertension symptoms are. There are four different classes - I is the mildest and IV the most severe form of pulmonary hypertension.

    Time frame: Baseline and 24 Weeks

  15. Number of Participants With One or More Adverse Events (AEs)

    An AE is any untoward medical occurrence in a study participant administered a pharmaceutical product that does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product, whether or not related to the medicinal product.

    Time frame: Up to 24 weeks

  16. Number of Participants Who Experienced One or More Events Indicative of Clinical Worsening of Pulmonary Arterial Hypertension (PAH)

    Events that indicate clinical worsening of PAH include death, need for and/or worsening-related listing for lung and/or heart transplant, need to initiate an approved PAH SOC rescue therapy, PAH-specific hospitalization, or functional deterioration (worsened WHO Functional Class AND 15% decrease in 6MWD).

    Time frame: Up to 102 weeks

  17. Observed Trough Concentration (Ctrough) of Sotatercept at Cycle 9

    Ctrough is the plasma concentration of a drug prior to administration.

    Time frame: Day 1 of Cycle 9 (Each cycle was 21 days.)

  18. Maximum Plasma Concentration (Cmax) of Sotatercept at Cycle 9

    Cmax is a measure of the maximum amount of drug in the plasma after the dose is given. PopPK modeling approach was used to build a population PK model that captures the totality of the observed data from Cycles 1 to 9. The Cmax parameter is derived from this preliminary popPK modeling.

    Time frame: Day 1 of each 21-day cycle: Cycles 1-9

  19. Minimum Plasma Concentration (Cmin) of Sotatercept at Cycle 9

    Cmin is a measure of the minimum amount of drug in the plasma after the dose is given. PopPK modeling approach was used to build a population PK model that captures the totality of the observed data from Cycles 1 to 9. The Cmin parameter is derived from this preliminary popPK modeling.

    Time frame: Day 1 of each 21-day cycle: Cycles 1-9

  20. Average Concentration (Cavg) of Sotatercept at Cycle 9

    Cavg is calculated by area under the plasma concentration versus dosing interval time curve at steady-state divided by the dosing interval. PopPK modeling approach was used to build a population PK model that captures the totality of the observed data from Cycles 1 to 9. The Cavg parameter is derived from this preliminary popPK modeling.

    Time frame: Day 1 of each 21-day cycle: Cycles 1-9

  21. Area Under the Concentration-Time Curve From 0 to T (AUC0-T) of Sotatercept at Cycle 9

    AUC0-T (area under the plasma concentration versus time curve from time zero after a dose is given to a period of one 21-day cycle) is a measure of the mean concentration levels of a drug in the plasma at steady state. PopPK modeling approach was used to build a population PK model that captures the totality of the observed data from Cycles 1 to 9. The AUC0-T parameter is derived from this preliminary popPK modeling.

    Time frame: Day 1 of each 21-day cycle: Cycles 1-9

  22. Apparent Terminal Half-life (t1/2 ) of Sotatercept at Cycle 9

    t1/2 is the elimination half-life of study drug: the time it takes for half of the study drug in the blood plasma to dissipate. PopPK modeling approach was used to build a population PK model that captures the totality of the observed data from Cycles 1 to 9. The t1/2 parameter is derived from this preliminary popPK modeling.

    Time frame: Day 1 of each 21-day cycle: Cycles 1-9

  23. Apparent Serum Clearance (CL) of Sotatercept at Cycle 9

    Apparent serum CL is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. PopPK modeling approach was used to build a population PK model that captures the totality of the observed data from Cycles 1 to 9. The apparent serum CL parameter is derived from this preliminary popPK modeling.

    Time frame: Day 1 of each 21-day cycle: Cycles 1-9

  24. Apparent Volume of Distribution (Vz/F) of Sotatercept at Cycle 9

    Vz/F is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. PopPK modeling approach was used to build a population PK model that captures the totality of the observed data from Cycles 1 to 9. The Vz/F parameter is derived from this preliminary popPK modeling.

    Time frame: Day 1 of each 21-day cycle: Cycles 1-9

  25. Absorption Rate Constant (Ka) of Sotatercept at Cycle 9

    Ka is the proportionality constant that relates the rate of drug absorbed into the body. Ka is a value used to describe the rate at which a drug enters into the system. It is expressed in units of time. PopPK modeling approach was used to build a population PK model that captures the totality of the observed data from Cycles 1 to 9. The Ka parameter is derived from this preliminary popPK modeling.

    Time frame: Day 1 of each 21-day cycle: Cycles 1-9

07

Results

Posted Feb 10, 2023

Participant flow

Base Study
Participant flow — Base Study
MilestoneSotatercept
Started21
Completed20
Not completed1
Withdrew: Withdrawal by subject1
Extension Study
Participant flow — Extension Study
MilestoneSotatercept
Started20
Completed19
Not completed1
Withdrew: Withdrawal by subject1

Outcome measures

PrimaryChange From Baseline in Peak Oxygen Uptake (VO2 Max) at 24 Weeks

Each participant's VO2 max was measured by an invasive cardiopulmonary exercise test (iCPET) at baseline and at 24 weeks.

Time frame:
Baseline and 24 weeks
Reported as:
Mean · mL/min/kg
Change From Baseline in Peak Oxygen Uptake (VO2 Max) at 24 Weeks
mL/min/kgSotatercept
Change From Baseline in Peak Oxygen Uptake (VO2 Max) at 24 Weeks1.28 ± 2.628
SecondaryChange From Baseline in Right Ventricular Stroke Volume (RV SV) at 24 Weeks

Each participant's RV SV was measured by cardiac MRI at baseline and at 24 weeks.

Time frame:
Baseline and 24 weeks
Reported as:
Mean · mL
Change From Baseline in Right Ventricular Stroke Volume (RV SV) at 24 Weeks
mLSotatercept
Change From Baseline in Right Ventricular Stroke Volume (RV SV) at 24 Weeks-27.306 ± 26.5786
SecondaryChange From Baseline in Right Ventricular End-Systolic Volume (RV ESV) at 24 Weeks

Each participant's RV ESV was measured by cardiac MR imaging at baseline and at 24 weeks.

Time frame:
Baseline and 24 weeks
Reported as:
Mean · mL
Change From Baseline in Right Ventricular End-Systolic Volume (RV ESV) at 24 Weeks
mLSotatercept
Change From Baseline in Right Ventricular End-Systolic Volume (RV ESV) at 24 Weeks-39.151 ± 22.5544
SecondaryChange From Baseline in Right Ventricular End-Diastolic Volume (RV EDV) at 24 Weeks

Each participant's RV EDV was measured by cardiac MR imaging at baseline and at 24 weeks.

Time frame:
Baseline and 24 weeks
Reported as:
Mean · mL
Change From Baseline in Right Ventricular End-Diastolic Volume (RV EDV) at 24 Weeks
mLSotatercept
Change From Baseline in Right Ventricular End-Diastolic Volume (RV EDV) at 24 Weeks-66.459 ± 37.3311
SecondaryPercent Change From Baseline in Right Ventricular Ejection Fraction (RV EF) at 24 Weeks

Each participant's RV EF was measured by cardiac MR imaging at baseline and at 24 weeks.

Time frame:
Baseline and 24 Weeks
Reported as:
Mean · Percent change
Percent Change From Baseline in Right Ventricular Ejection Fraction (RV EF) at 24 Weeks
Percent changeSotatercept
Percent Change From Baseline in Right Ventricular Ejection Fraction (RV EF) at 24 Weeks-1.3 ± 8.48
SecondaryChange From Baseline in Right Ventricular Stroke Volume Index (RV SVI) at 24 Weeks

Each participant's RV SVI was measured by cardiac MR imaging at baseline and at 24 weeks.

Time frame:
Baseline and 24 weeks
Reported as:
Mean · mL/m^2
Change From Baseline in Right Ventricular Stroke Volume Index (RV SVI) at 24 Weeks
mL/m^2Sotatercept
Change From Baseline in Right Ventricular Stroke Volume Index (RV SVI) at 24 Weeks-15.073 ± 14.8219
SecondaryChange From Baseline in Right Ventricular (RV) Mass at 24 Weeks

Each participant's RV mass was measured by cardiac MR imaging at baseline and at 24 weeks.

Time frame:
Baseline and 24 weeks
Reported as:
Mean · grams
Change From Baseline in Right Ventricular (RV) Mass at 24 Weeks
gramsSotatercept
Change From Baseline in Right Ventricular (RV) Mass at 24 Weeks-6.240 ± 13.3558
SecondaryChange From Baseline in Ventilatory Efficiency (VE/VCO2 Slope) at 24 Weeks

VE/VCO2 slope refers to the slope of the regression line of Minute Ventilation (VE) in liters/minute in the Y-axis and corresponding carbon dioxide production per minute (VCO2) in liters/minute in the X-axis plotted with multiple measurements taken during exercise. Each participant's VE/VCO2 slope at peak exercise was measured by an iCPET at baseline and at 24 weeks.

Time frame:
Baseline and 24 weeks
Reported as:
Mean · Unitless
Change From Baseline in Ventilatory Efficiency (VE/VCO2 Slope) at 24 Weeks
UnitlessSotatercept
Change From Baseline in Ventilatory Efficiency (VE/VCO2 Slope) at 24 Weeks-8.87 ± 12.298
SecondaryChange From Baseline in Cardiac Index at 24 Weeks

Each participant's cardiac index at peak exercise was measured by iCPET at baseline and at 24 weeks.

Time frame:
Baseline and 24 weeks
Reported as:
Mean · Liter/min/m^2
Change From Baseline in Cardiac Index at 24 Weeks
Liter/min/m^2Sotatercept
Change From Baseline in Cardiac Index at 24 Weeks0.411 ± 1.1944
SecondaryChange From Baseline in Mean Pulmonary Arterial Pressure at 24 Weeks

Each participant's pulmonary arterial pressure at peak exercise was measured by iCPET at baseline and at 24 weeks.

Time frame:
Baseline and 24 weeks
Reported as:
Mean · mmHg
Change From Baseline in Mean Pulmonary Arterial Pressure at 24 Weeks
mmHgSotatercept
Change From Baseline in Mean Pulmonary Arterial Pressure at 24 Weeks-14.9 ± 13.22
SecondaryChange From Baseline in Arteriovenous O2 Content Difference (Ca-vO2) at 24 Weeks

Each participant's Ca-vO2 at peak exercise was measured by iCPET at baseline and at 24 weeks.

Time frame:
Baseline and 24 weeks
Reported as:
Mean · mL/100 mL
Change From Baseline in Arteriovenous O2 Content Difference (Ca-vO2) at 24 Weeks
mL/100 mLSotatercept
Change From Baseline in Arteriovenous O2 Content Difference (Ca-vO2) at 24 Weeks0.63 ± 2.131
SecondaryChange From Baseline in Pulmonary Vascular Resistance (PVR) at 24 Weeks

Each participant's PVR, at resting supine, was measured by right heart catheterization (RHC) at baseline and at 24 weeks.

Time frame:
Baseline and 24 weeks
Reported as:
Mean · dynes*sec/cm^5
Change From Baseline in Pulmonary Vascular Resistance (PVR) at 24 Weeks
dynes*sec/cm^5Sotatercept
Change From Baseline in Pulmonary Vascular Resistance (PVR) at 24 Weeks-305.728 ± 313.9827
SecondaryChange From Baseline in 6-Minute Walk Distance (6MWD) at 24 Weeks

6MWD is measured by an exercise test known as 6MWT that assesses aerobic capacity and endurance. It measures the distance covered over a time of 6 minutes and is used as an outcome measure by which to compare changes in performance capacity. Each participant's 6MWD was measured at baseline and at 24 weeks. An increase in the distance walked during the 6MWT indicates improvement in basic mobility.

Time frame:
Baseline and 24 weeks
Reported as:
Mean · meters
Change From Baseline in 6-Minute Walk Distance (6MWD) at 24 Weeks
metersSotatercept
Change From Baseline in 6-Minute Walk Distance (6MWD) at 24 Weeks66.35 ± 85.659
SecondaryChange From Baseline in Concentration of Amino-Terminal Brain Natriuretic Propeptide (NT-proBNP) at 24 Weeks

Each participant's laboratory biomarkers N-terminal prohormone brain-type natriuretic peptide (NT-proBNP) or brain-type natriuretic peptide (BNP) were measured at baseline and at 24 weeks.

Time frame:
Baseline and 24 Weeks
Reported as:
Mean · pg/mL
Change From Baseline in Concentration of Amino-Terminal Brain Natriuretic Propeptide (NT-proBNP) at 24 Weeks
pg/mLSotatercept
Change From Baseline in Concentration of Amino-Terminal Brain Natriuretic Propeptide (NT-proBNP) at 24 Weeks-623.1 ± 840.56
SecondaryChange From Baseline in WHO (World Health Organization) Functional Class at 24 Weeks

The World Health Organization (WHO) functional class describes how severe a person's pulmonary hypertension symptoms are. There are four different classes - I is the mildest and IV the most severe form of pulmonary hypertension.

Time frame:
Baseline and 24 Weeks
Reported as:
Mean · WHO functional class
Change From Baseline in WHO (World Health Organization) Functional Class at 24 Weeks
WHO functional classSotatercept
Change From Baseline in WHO (World Health Organization) Functional Class at 24 Weeks-0.76 ± 0.903
SecondaryNumber of Participants With One or More Adverse Events (AEs)

An AE is any untoward medical occurrence in a study participant administered a pharmaceutical product that does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product, whether or not related to the medicinal product.

Time frame:
Up to 24 weeks
Reported as:
Count of participants · Participants
Number of Participants With One or More Adverse Events (AEs)
ParticipantsSotatercept
Number of Participants With One or More Adverse Events (AEs)20
SecondaryNumber of Participants Who Experienced One or More Events Indicative of Clinical Worsening of Pulmonary Arterial Hypertension (PAH)

Events that indicate clinical worsening of PAH include death, need for and/or worsening-related listing for lung and/or heart transplant, need to initiate an approved PAH SOC rescue therapy, PAH-specific hospitalization, or functional deterioration (worsened WHO Functional Class AND 15% decrease in 6MWD).

Time frame:
Up to 102 weeks
Reported as:
Count of participants · Participants
Number of Participants Who Experienced One or More Events Indicative of Clinical Worsening of Pulmonary Arterial Hypertension (PAH)
ParticipantsSotatercept
Number of Participants Who Experienced One or More Events Indicative of Clinical Worsening of Pulmonary Arterial Hypertension (PAH)1
SecondaryObserved Trough Concentration (Ctrough) of Sotatercept at Cycle 9

Ctrough is the plasma concentration of a drug prior to administration.

Time frame:
Day 1 of Cycle 9 (Each cycle was 21 days.)
Reported as:
Mean · ng/mL
Observed Trough Concentration (Ctrough) of Sotatercept at Cycle 9
ng/mLSotatercept
Observed Trough Concentration (Ctrough) of Sotatercept at Cycle 95884.79 ± 2933.77
SecondaryMaximum Plasma Concentration (Cmax) of Sotatercept at Cycle 9

Cmax is a measure of the maximum amount of drug in the plasma after the dose is given. PopPK modeling approach was used to build a population PK model that captures the totality of the observed data from Cycles 1 to 9. The Cmax parameter is derived from this preliminary popPK modeling.

Time frame:
Day 1 of each 21-day cycle: Cycles 1-9
Reported as:
Mean · ng/mL
Maximum Plasma Concentration (Cmax) of Sotatercept at Cycle 9
ng/mLSotatercept
Maximum Plasma Concentration (Cmax) of Sotatercept at Cycle 99732.785 ± 2852.373
SecondaryMinimum Plasma Concentration (Cmin) of Sotatercept at Cycle 9

Cmin is a measure of the minimum amount of drug in the plasma after the dose is given. PopPK modeling approach was used to build a population PK model that captures the totality of the observed data from Cycles 1 to 9. The Cmin parameter is derived from this preliminary popPK modeling.

Time frame:
Day 1 of each 21-day cycle: Cycles 1-9
Reported as:
Mean · ng/mL
Minimum Plasma Concentration (Cmin) of Sotatercept at Cycle 9
ng/mLSotatercept
Minimum Plasma Concentration (Cmin) of Sotatercept at Cycle 96234.303 ± 2466.046
SecondaryAverage Concentration (Cavg) of Sotatercept at Cycle 9

Cavg is calculated by area under the plasma concentration versus dosing interval time curve at steady-state divided by the dosing interval. PopPK modeling approach was used to build a population PK model that captures the totality of the observed data from Cycles 1 to 9. The Cavg parameter is derived from this preliminary popPK modeling.

Time frame:
Day 1 of each 21-day cycle: Cycles 1-9
Reported as:
Mean · ng/mL
Average Concentration (Cavg) of Sotatercept at Cycle 9
ng/mLSotatercept
Average Concentration (Cavg) of Sotatercept at Cycle 98221.907 ± 2749.846
SecondaryArea Under the Concentration-Time Curve From 0 to T (AUC0-T) of Sotatercept at Cycle 9

AUC0-T (area under the plasma concentration versus time curve from time zero after a dose is given to a period of one 21-day cycle) is a measure of the mean concentration levels of a drug in the plasma at steady state. PopPK modeling approach was used to build a population PK model that captures the totality of the observed data from Cycles 1 to 9. The AUC0-T parameter is derived from this preliminary popPK modeling.

Time frame:
Day 1 of each 21-day cycle: Cycles 1-9
Reported as:
Mean · ng*day/mL
Area Under the Concentration-Time Curve From 0 to T (AUC0-T) of Sotatercept at Cycle 9
ng*day/mLSotatercept
Area Under the Concentration-Time Curve From 0 to T (AUC0-T) of Sotatercept at Cycle 9172659.953 ± 57746.622
SecondaryApparent Terminal Half-life (t1/2 ) of Sotatercept at Cycle 9

t1/2 is the elimination half-life of study drug: the time it takes for half of the study drug in the blood plasma to dissipate. PopPK modeling approach was used to build a population PK model that captures the totality of the observed data from Cycles 1 to 9. The t1/2 parameter is derived from this preliminary popPK modeling.

Time frame:
Day 1 of each 21-day cycle: Cycles 1-9
Reported as:
Mean · Days
Apparent Terminal Half-life (t1/2 ) of Sotatercept at Cycle 9
DaysSotatercept
Apparent Terminal Half-life (t1/2 ) of Sotatercept at Cycle 921.919 ± 5.861
SecondaryApparent Serum Clearance (CL) of Sotatercept at Cycle 9

Apparent serum CL is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. PopPK modeling approach was used to build a population PK model that captures the totality of the observed data from Cycles 1 to 9. The apparent serum CL parameter is derived from this preliminary popPK modeling.

Time frame:
Day 1 of each 21-day cycle: Cycles 1-9
Reported as:
Mean · Liters/day
Apparent Serum Clearance (CL) of Sotatercept at Cycle 9
Liters/daySotatercept
Apparent Serum Clearance (CL) of Sotatercept at Cycle 90.213 ± 0.077
SecondaryApparent Volume of Distribution (Vz/F) of Sotatercept at Cycle 9

Vz/F is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. PopPK modeling approach was used to build a population PK model that captures the totality of the observed data from Cycles 1 to 9. The Vz/F parameter is derived from this preliminary popPK modeling.

Time frame:
Day 1 of each 21-day cycle: Cycles 1-9
Reported as:
Mean · Liters
Apparent Volume of Distribution (Vz/F) of Sotatercept at Cycle 9
LitersSotatercept
Apparent Volume of Distribution (Vz/F) of Sotatercept at Cycle 93.969 ± 1.078
SecondaryAbsorption Rate Constant (Ka) of Sotatercept at Cycle 9

Ka is the proportionality constant that relates the rate of drug absorbed into the body. Ka is a value used to describe the rate at which a drug enters into the system. It is expressed in units of time. PopPK modeling approach was used to build a population PK model that captures the totality of the observed data from Cycles 1 to 9. The Ka parameter is derived from this preliminary popPK modeling.

Time frame:
Day 1 of each 21-day cycle: Cycles 1-9
Reported as:
Mean · 1/day
Absorption Rate Constant (Ka) of Sotatercept at Cycle 9
1/daySotatercept
Absorption Rate Constant (Ka) of Sotatercept at Cycle 90.280 ± 0.035

Adverse events

Collected over Treatment period: Up to 24 weeks; Extension period: Up to 18 months plus 8-week follow-up period.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Sotatercept Treatment Period0/21 (0%)4/21 (19%)14/21 (66.7%)
Sotatercept Extension Period0/20 (0%)2/20 (10%)18/20 (90%)
Most frequent serious events
Most frequent serious events
EventSotatercept Treatment PeriodSotatercept Extension Period
HyponatraemiaMetabolism and nutrition disorders0/211/20
HaemoptysisRespiratory, thoracic and mediastinal disorders0/211/20
HaematocheziaGastrointestinal disorders1/210/20
Complication associated with deviceGeneral disorders1/210/20
HypervolaemiaMetabolism and nutrition disorders1/210/20
Device leakageProduct Issues1/210/20
Most frequent other events
Showing 10 of 27
Most frequent other events
EventSotatercept Treatment PeriodSotatercept Extension Period
PolycythaemiaBlood and lymphatic system disorders3/215/20
Pain in extremityMusculoskeletal and connective tissue disorders3/215/20
EpistaxisRespiratory, thoracic and mediastinal disorders1/215/20
NauseaGastrointestinal disorders2/214/20
Chest painGeneral disorders0/214/20
Peripheral swellingGeneral disorders0/213/20
HeadacheNervous system disorders3/213/20
FatigueGeneral disorders3/212/20
ArthralgiaMusculoskeletal and connective tissue disorders3/210/20
DiarrhoeaGastrointestinal disorders1/212/20

Baseline characteristics

Age, Continuous
Age, Continuous(years)Sotatercept
Mean45.3 ± 15.06
Sex: Female, Male
Sex: Female, Male(Participants)Sotatercept
Female17
Male4
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Sotatercept
Hispanic or Latino6
Not Hispanic or Latino15
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Sotatercept
American Indian or Alaska Native1
Asian2
Native Hawaiian or Other Pacific Islander1
Black or African American0
White17
More than one race0
Unknown or Not Reported0
Peak Oxygen Uptake (VO2 max) at Baseline
Peak Oxygen Uptake (VO2 max) at Baseline(mL/min/kg)Sotatercept
Mean11.02 ± 3.204
08

Study locations

4 sites
  • The University of Arizona
    Tucson, Arizona 85724, United States
  • Brigham and Women's Hospital
    Boston, Massachusetts 02115, United States
  • Mayo Clinic
    Rochester, Minnesota 55905, United States
  • University of Pittsburgh Medical Center
    Pittsburgh, Pennsylvania 15213, United States
09

References and documents

Publications

  • Waxman AB, Systrom DM, Manimaran S, de Oliveira Pena J, Lu J, Rischard FP. SPECTRA Phase 2b Study: Impact of Sotatercept on Exercise Tolerance and Right Ventricular Function in Pulmonary Arterial Hypertension. Circ Heart Fail. 2024 May;17(5):e011227. doi: 10.1161/CIRCHEARTFAILURE.123.011227. Epub 2024 Apr 4. PubMed 38572639 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2019 to primary completion in Dec 2021, 32 months.

Results were first posted in Feb 2023, 1 year 1 month after primary completion.

Of 28 industry-sponsored phase 2 interventional studies under Pulmonary Arterial Hypertension, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 48. This study's 32 months is close to that.

Counting every sponsor, half of 51 studies reached it within 44 months; a quarter within 26 and three quarters within 65.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 2, 2018
First posted
Nov 13, 2018
StartActual
Apr 19, 2019
Primary completionActual
Dec 21, 2021
CompletionActual
Mar 22, 2022
Results first posted
Feb 10, 2023
Last update
Aug 27, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 27, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03738150
Responsible party
Sponsor
First posted
Nov 13, 2018
Start date
Apr 19, 2019
Primary completion
Dec 21, 2021
Completion
Mar 22, 2022
Results posted
Feb 10, 2023
Last update
Aug 27, 2024

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC
Jonathan Lu, MD
study director · Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sotatercept

Start the discussion